Gemtuzumab Receives New FDA Approval for Acute Myeloid Leukemia

FDA has approved gemtuzumab ozogamicin (Mylotarg™) for adults with newly diagnosed CD33-positive AML and patients 2 years and older with CD33-positive AML who have experienced a relapse or whose disease has not responded to initial treatment.

Cancer Currents: An NCI Cancer Research Blog